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Background. Caffeic acid phenethyl ester (CAPE) has been reported to possess time-dependent fibrinolytic activity by in
vitro assay. This study is aimed at investigating fibrinolytic dose-dependent activity of CAPE using in vitro assays. Methods.
Standardized human whole blood (WB) clots were incubated in either blank controls or different concentrations of CAPE
(3.75, 7.50, 15.00, 22.50, and 30.00mM). After 3 hours, D-dimer (DD) levels and WB clot weights were measured for each
concentration. Thromboelastography (TEG) parameters were recorded following CAPE incubation, and fibrin morphology
was examined under a confocal microscope. Results. Overall, mean DD (𝜇g/mL) levels were significantly different across
samples incubated with different CAPE concentrations, and the median pre- and postincubation WB clot weights (grams)
were significantly decreased for each CAPE concentration. Fibrin removal was observed microscopically and indicated dose-
dependent effects. Based on the TEG test, the Ly30 fibrinolytic parameter was significantly different between samples incubated
with two different CAPE concentrations (15.0 and 22.50mM). The 50% effective dose (ED50) of CAPE (based on DD) was
1.99mg/mL. Conclusions. This study suggests that CAPE possesses fibrinolytic activity following in vitro incubation and that it
has dose-dependent activities. Therefore, further investigation into CAPE as a potential alternative thrombolytic agent should be
conducted.
1. Introduction
For decades, fibrinolytic (thrombolytic) therapy has been
an important means of establishing reperfusion [1]. Throm-
bolytic agents, which activate plasminogen to form plas-
min, lead to accelerated lysis of thrombi. Thrombolytics
are applied in the treatment of acute myocardial infarction,
acute pulmonary embolism, and deep vein thrombosis. For
example, thrombolytic therapy administered within 12 hrs of
a heart attack may increase the chances of survival. However,
limitations to the use of thrombolytic therapy include per-
ceived or definite contradictions and intracranial bleeding in
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cardiovascular diseases [2–5]. Therefore, thrombolytic ther-
apy is only limited to very few pathological conditions that
have limited complications.
Thrombolytic drugs used clinically are basically divided
into three generations. First-generation thrombolytics in-
clude streptokinase (SK) and urokinase (UK). Second-gen-
eration drugs include tissue plasminogen activator (t-PA)
and single-chain urokinase-type plasminogen activator (scu-
PA, or prourokinase, pro-UK).The third generation includes
novel agents produced from the first- or second-generation
thrombolytic agents based on modern molecular biology
techniques. However, even with widespread use, they have
been reported to potentially cause bleeding complications,
have a short half-life, exhibit low fibrin specificity, are costly,
may contribute to allergic reactions, and require administra-
tion of large therapeutic doses [2–6].
Propolis is a resinous hive product collected by honey-
bees from various plant sources. Depending on its source
and age, it may vary from yellow-green to dark brown. It
contains many compounds including amino acids, phenolic
compounds, and flavonoid compounds [7–15]. Caffeic acid
phenethyl ester (CAPE) is a plant-derived phenolic com-
pound that is an active component of honey and propolis
from honeybee hives [16]. CAPE has antithrombotic (by
modulating tissue factor expression at a posttranscriptional
level in endothelial cells) [17], antiviral, antibacterial, anti-
inflammatory [18, 19], anticancer [20], antiatherosclerotic,
antioxidative [16, 19, 21], immunostimulatory, and tumor
growth inhibition activities. CAPE has also been shown to
be a potential inhibitor of some enzymes including ornith-
ine carboxylase, 5-areductase, protease, lipoxygenase, cy-
clooxygenase, and human immunodeficiency virus- (HIV-) 1
integrase [22].
Previous studies [5, 7, 23] have reported various fibrin-
olytic enzymes that are contained in different Asian foods
including Tofuyo, Korean Chung kook-Jang soy sauce, Jap-
anese Natto, edible honey mushrooms, and cheonggukjang
kinase 3–5 (CGK). These enzymes have been shown to con-
vert proenzyme plasminogen into serine protease plasmin
and play a vital role in fibrinolysis [5, 7, 23]. In addition, the
Bacillus subtilisK42 isolated from soybean flour has also been
reported to have thrombolytic potential [24]. Some addi-
tional examples include the use of a recombinant CGK-rich
fraction isolated from cheonggukjang [25] as a thrombolytic
and fibrinolytic agent and B. Subtilis LD-8547 culture broth,
which is another useful thrombolytic agent [26].
Currently, there are limited studies on the in vitro assess-
ment of fibrinolytic potentials of various compounds. Some
evidence of fibrinolysis has been found in whole blood (WB)
clots that exhibited different patterns of fibrin morphology
when viewed on a confocal microscope using streptokinase
[27]. Plasma clotting has also been described as an alternative
method to study in vitro fibrinolytic activity. One study
utilized plasma clots and washed red blood cells (RBCs) at
different concentrations to determine the effects of RBCs
on fibrin clot structure by confocal microscopy. The authors
noted that different concentrations led to heterogeneity in
fibrin network structure [28, 29]. Another study reported that
CAPE has time-dependent in vitro fibrinolytic activity [30].
However, to date, no study has been conducted to investigate
the dose-dependent effects of CAPE on fibrinolysis. If the
dose-dependent effect of CAPE can be determined, it will
provide evidence for further investigation into the use of
CAPE as a potential new fibrinolytic agent.
2. Materials and Methods
The present study was approved by the local institutional
ethical committee, Universiti Sains Malaysia, with the ethical
numbers: FWA 00007718 and IRB Reg number: 00004494.
The fibrinolytic activity of CAPE at different concentrations
was measured using a previously reported method, which
was used to demonstrate that CAPE has time-dependent
fibrinolytic activity at 3, 6, and 9 hrs [30]. The WB clot lysis
method to study fibrinolysis was performed according to
previously reported procedures [27, 30]. Various in vitro fibri-
nolytic assessments were performed including D-dimer tests
(DD), WB clot weight measurements, thromboelastography
(TEG) assays, and morphological assessment of fibrin by
confocal microscopy.
TEG was performed on WB clots because it allows a
global assessment of hemostatic activities. TEG overcomes
the limitations of conventional coagulation tests and provides
an inclusive overview of hemostasis, starting from early
thrombin production to the formation of fibrin strands and
fibrinolysis. Moreover, TEG with defined parameters reflects
the integrity of particular hemostatic components [31–34].
DD is a specific product of fibrinolysis, and the quantitative
measurement of DD assesses the extent of fibrinolysis at
the molecular level. Moreover, modern automation of the
coagulometer permits the direct quantitation of DD.WB clot
weight is an indirect marker of fibrinolysis that measures
clot disintegration, which reduces the clot weight over time.
Lastly, morphological assessment of fibrin is best done by
confocal or electron microscopy, which could reveal the mi-
crochanges in fibrin structure during the fibrinolytic process.
Standardized human WB clots were incubated for 3 hrs
in pooled platelet-poor plasma (PPP) (as a normal control),
5% dimethyl sulphoxide (DMSO) (as a solvent control), or
CAPE at different concentrations (3.75, 7.50, 15.00, 22.50,
or 30.00mM). DD was measured from the supernatant of
PPP-, DMSO-, and CAPE-treated clots (at the various stated
concentrations). WB clots were weighed before and after
incubation, and WB clots were examined for fibrin structure
using a specific dye under a confocal microscope (Carl Zeiss,
Jena, Germany). In this study, different CAPE concentrations
from 3.75 to 30.00mM were investigated based on previous
reports in which 15mM CAPE exhibited fibrinolytic activity
[30]. The WB clots and PPP were prepared first, followed by
fibrinolytic assessment of CAPE by theWB clot lysis method.
(i) WB Clot Preparation. Standardized WB clots were pre-
pared from 4.50mL of venous blood derived from a healthy
volunteer with blood group O positive (𝑛 = 10). The whole
blood was then transferred into three different preweighed,
sterile siliconized, plain glass tubes (12 × 75mm). Each tube
contained 1.50mL WB without anticoagulant and the blood
was allowed to clot at room temperature for 10min. Prior to
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the incubation in water bath, the blood containing tubes were
coveredwith parafilm to avoid contamination andhaemolysis
by water evaporation. After that, the tubes were incubated in
a temperature-controlled water bath (Grant SUB6, England)
at 37∘C for 3 hrs to ensure complete clot retraction and
separation of the clot from the edges of the tubes. After clot
retraction the serum was carefully removed from the edges
of the glass tube using a Pasteur pipette without disturbing
the clot. Finally, the tubes were completely dried using filter
paper (125mm). The weight of the tube together with the
clot was determined using an electronic balance (AND FR-
200 MK II, Japan). The WB clot weight was estimated by
calculating the difference between the weight of the tube
containing the clot and theweight of an empty tube.The tubes
withWB clots were properly labeled for further experiments.
The WB clot weight used in this study was standardized to
0.70 ± 0.15 grams.
(ii) Preparation of Normal Pooled Plasma (for Normal Control
and as Diluents). Human pooled PPP was prepared and
was strictly processed by collecting 9.00mL of WB into
two trisodium citrate tubes (4.5mL each) from participants
with O blood group (𝑛 = 20). Blood was drawn using
an evacuated tube system with multisample green sterile
needle (21 G). Immediately after blood collection, the samples
were centrifuged (Eppendorf, 5810 R, Germany) at 1500×g
for 15min at room temperature. Then, the supernatant was
centrifuged at 1200×g for 15min. The procedure was carried
out according to the Clinical Laboratory Standardization
Institute (CLSI) guidelines for coagulation tests.
The PPP from all the participants was pooled and sample
integrity was tested using coagulation parameters. The tests
included prothrombin time (PT), activated partial prothrom-
bin time (APTT), fibrinogen, DD level, and factor VIII
activity using STA-R Evolution coagulation analyzer (Stago,
Asnie`res, France). Von Willebrand factor antigen was also
measured using specific reagents of the system based on the
protocol provided with kits for the ACL Elite PRO (Belford,
USA). The tests were performed to ensure that normal PPP
was obtained for the study. The yielded pooled PPP was then
aliquoted into small volumes in different centrifuge tubes
(BD biosciences, San Jose, USA) and was stored at −80∘C
deep freezer for 6 months according to the CLSI guideline
for coagulation assays.
2.1.WBClot LysisMethod for Fibrinolytic Assessment of CAPE.
Commercially available pure CAPE powder was purchased
from Sigma Company (Aldrich, USA). The CAPE solution
was prepared in DMSO solution as per the previously
reported procedure and manufacturer’s instructions [30]. In
the present study, a 3.6M CAPE stock solution was prepared
and stored at −20∘C. The stock solution was thawed at room
temperature and used for the preparation of dilutions to
measure fibrinolytic activity.
Different concentrations of CAPE (3.75, 7.50, 15.00, 22.50,
and 30.00mM) were prepared using pooled PPP as the
diluent. The WB clots were immersed in each dilution and
incubated in a temperature-controlled water bath at 37∘C for
3 hrs. After incubation, the pooled PPP was transferred into
a microcentrifuge tube (bullet tube) using a Pasteur pipette
after gentle shaking of the clot. The plasma was centrifuged
at 1200×g for 5min, and the supernatant was separated for
DD measurement using coagulation analyzer as mentioned
above. After removal of the plasma, the clots were weighted
by calculating from the differences of the weight of the tube
before incubation and the weight after incubation (WB clot
weight =weight of tube containingWB clot before incubation
− weight of tube containing WB clot after incubation). A
similar procedure was repeated for 10 times to measure the
changes of DD andWB clot weight following treatment with
CAPE. The 50% effective dose (ED50) was calculated using
Excel (Microsoft, USA). Similar tests were also performed for
the controls as described below.
2.2. WB Clot Incubated in Pooled PPP (Normal Control)
and 0.5% DMSO (Solvent Control). One milliliter of each
control (pooled PPP and 0.5% DMSO diluted in pooled
PPP) was added to a tube containing a WB clot (method
described as above), which was then covered by parafilm.
The tubes were incubated in a temperature-controlled water
bath at 37∘C for 3 hrs. Following incubation, the plasma was
transferred to a microcentrifuge tube (bullet tube) using a
Pasteur pipette. The weight of each glass tube containing the
clot after incubation was measured and the clot weight was
calculated by taking the difference between the preincubation
WB clot weight and the postincubation WB clot weight.
The plasma collected in the bullet tube was centrifuged at
1200×g for 5min, and the supernatant was separated for DD
quantitation using coagulation analyzer (as described below).
Thewhole procedure was carried out 10 times tomeasure clot
weights and DD levels.
2.3. Quantitation of D-Dimer. Quantitation of DD levels was
performed using the STA-R Evolution coagulation analyzer
and was photometrically determined by the immunoturbidi-
metric method using the Liatest kit (Stago, Asnie`res, France).
This test was performed according to the manufacturer’s
protocol.
2.4. Confocal Microscopy Protocol and Staining Procedure.
Confocal microscopic observations of WB clots were con-
ducted as per a previously described method [27] with some
slight modifications [28, 29, 35] to suit the conditions in
this study. Briefly, stock solution was prepared by dissolving
5mg of fibrinogen in 3.30mL of 0.1M sodium bicarbonate
(NaHCO
3
) (pH 8.3) at room temperature. The solution was
stored at 4∘C for further use. Subsequently, aworking solution
was prepared by adding 100 𝜇L of fibrinogen (stock) dye
to distilled water (6mL) followed by solubilization with
occasional gentle mixing for one hour using a mechanical
stirrer. Fibrinogen fluorescence dye [Alexa Fluor 488 human
fibrinogen conjugates (F-13191)] purchased from Molecular
Probes (USA) was used in this study.
The working solution (0.3M) of merocyanine 540 fluo-
rescent (erythrocyte dye) was prepared by dissolving 3.4mg
in 20mL of distilled water. Phosphate-buffered saline (PBS)
was used as a washing buffer in this study. Another buffer
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of 0.1M NaHCO
3
was used as the diluent for the fibrinogen
fluorescence dye.
For confocal microscopic observations of WB clots, ve-
nous blood (5mL) obtained from O blood group volunteers
was used. WB (180𝜇L) was placed in each well of an 8-cham-
ber polystyrene vessel with a tissue culture-treated glass slide
(BD falcon cultures, USA) according to the ratio used forWB
clot lysis described above.
The chamber was allowed to stand for 10min at room
temperature and was then incubated in a temperature-
controlled water bath at 37∘C for 3 hrs to ensure complete
clot retraction. After incubation, the serum was completely
removed from the chambers. Then, retracted WB clots
without CAPE (group 1, controls) or in 120𝜇L of CAPE
(group 2) at different concentrations (3.75, 7.50, 15.00, 22.50,
and 30.00mM) were added to the WB clot in the chambers.
The chamber was labeled accordingly and incubated in a
temperature-controlled water bath at 37∘C for 3 hrs. The
CAPE (group 2) was carefully removed, and the WB clots
were washed with PBS for 3–5min. The washing was then
repeated 3 times. The fibrin fibers were labeled with 600𝜇L
of freshly prepared working solution of the primary antibody
Alexa Fluor 488 human fibrinogen conjugate F-13191 before
incubation at room temperature andwere then left in the dark
for 15min to avoid exposure to direct light.
After 15min, the stain was removed, and the clot was
washed 3 times with PBS. Then, it was incubated with
buffer at room temperature for 5min. Afterwards, the buffer
was removed, and 600 𝜇L of the merocyanine label (RBC-
emission wavelength 520 nm; Molecular Probe USA) was
added to the WB clot for red blood cell (RBC) staining.
It was then incubated at room temperature for 45min in
the dark. The dye was washed using PBS for 3–5min, and
the procedure was repeated 3 times. Antifade fluorescence
mounting medium was added, followed by examination on
a confocal microscope. Images of fibrin and RBCs for each
group were obtained on a Pascal 5 Axiovert inverted laser
confocal microscope with a 63x lens using an argon and
helium-neon (HeNe) laser. For confocal imaging of retracted
WB clots, Alexa 488 labels fibrin fibers green, and the
merocyanine 540 fluorescent dye (MC-540) labels the RBC
membranes are red [27].
2.5.Thromboelastography (TEG)Assay Procedure. Acomput-
erized coagulation analyzer (TEGmodel 5000; Haemoscope,
Niles, IL 60714, USA) was used to test the citrated blood
positioned in oscillating cups at 37∘C with the pin hanging
from the torsion wire into the blood sample.The fibrin strand
formation joins the motion of the cup to the pin. The trace is
then displayed on the computer screen where the deviation
in the trace is proportional to the clot strength. This method
was based on the methods described in previous studies and
reports [31, 32, 36]. Citrated whole blood (4.5mL) from nine
healthy volunteers (𝑛 = 9) was tested, and the specimens
were carefully checked for fibrin clots prior to testing to
detect other contaminating materials. One milliliter of blood
was pipetted into each kaolin tube for the normal control or
was incubated with CAPE at different concentrations (15.00
and 22.50mM) or 0.5% DMSO as a solvent control. For the
TEG study, only two concentrations were assessed. These
tubes were incubated for 3 hrs at 37∘C. Subsequently, 20 𝜇L
of calcium chloride (0.2mol/L) was added to a standard
specimen cup. After the samplewas adequatelymixed, 340 𝜇L
of citrated whole blood was added to the cup, and the assay
was run for at least 90min until completion of the meas-
urement of clot lysis at 30min.
TEG parameters that represent different aspects of
hemostasis were measured (𝑅, 𝐾, 𝛼, MA, and LY30). 𝑅
represents the time which elapsed from baseline until the
first fibrin clot was formed. The cut-off point is when the
amplitude reaches 2mm. Clot kinetics (𝐾) are measured
from the time of clot formation until an amplitude of
20mm is reached. Alpha (𝛼) is the angle starting from the
point of the clot reaction that represents the acceleration of
fibrin production and cross-linking. MA is the maximum
amplitude of the graph from the clot kinetic activity, which
reflects the greatest strength of the clot. It is a function of
both the fibrin and the platelet dynamic properties. LY30
represents the clot lysis 30min afterMA is reached, indicating
the rate of fibrinolytic activity [31, 34].
2.6. Statistical Analysis. Statistical analyses were performed
using PASW Statistics 20 (SPSS, Chicago, IL). Fibrinolytic
data using DD were analyzed using a parametric one-way
analysis of variance (ANOVA) test because the data were
normally distributed. The WB clot weights before and after
plasma incubation and following CAPE treatment were
compared using a nonparametricWilcoxon Signed Rank test
(because the data were not normally distributed). For the
TEG parameters, the normality test also revealed that the
results obtained for the parameters were not normally dis-
tributed; therefore, the data were analyzed using a Kruskal-
Wallis test. Multiple Mann-Whitney tests with Bonferroni
correction were applied. The level of significance was set as
<0.05.
3. Results
A preliminary study was conducted using various incubation
times to investigate the fibrinolytic effect of CAPE on DD
levels, and the results of DD tests performed after 1 to 9 hrs of
incubation were compared.The incubation times at 3 hrs and
above showed consistent results and significant differences in
DD (data not shown here). Previously, CAPE was shown to
have time-dependent fibrinolytic activity [30]. In the current
study, the fibrinolytic effects exhibited by CAPE at different
concentrations were investigated and showed significant
differences in mean DD after incubation with various CAPE
concentrations: 3.75, 7.50, 15.00, 22.50, and 30.00mM (except
at 15.00 versus 30.00mM and 22.50 versus 30.00mM).
There was no significant difference in mean DD levels
between the normal control (PPP) 0.27 (SD = 0.03) and 0.5%
DMSO solvent control 0.27 (SD = 0.05). On the other hand,
there was a reduction in DD after incubation of 22.50mM
CAPE (Figure 1), with a 50% effective dose (ED50) of CAPE
of 1.99mg/mL.
There was a statistically significant reduction in postin-
cubation clot weight compared to preincubation clot weight
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Figure 1: Fibrinolytic activity of CAPE.
using the different CAPE concentrations. Furthermore, the
weights of the WB clots following CAPE incubation were
significantly lower than the preincubation clot weights at all
concentrations. The median WB clot weights between the
various CAPE concentrations showed no significant differ-
ences except for 22.50 compared with 3.75mM, 7.50mM, and
15.00mM.
3.1. Confocal Microscopy. The in vitro experiments were
performed using retractedWB clots incubated in pooled PPP
and CAPE at different concentrations. The fibrin fibers were
removed from theWB clots in a manner proportionate to the
concentrations of CAPE. At the lower concentrations of 3.75
and 7.50mM, there was less fibrin than in the untreated clots
(control). At these two concentrations, the RBCs appeared
orange in color due to the combination of red (RBCs) and
green (fibrin) coloring which completely disappeared at the
higher concentrations, 15.00, 22.50, and 30.00mM, where
only red coloringwas present, reflecting the presence of RBCs
only and the absence of fibrin (Figure 2).
3.2. Thromboelastograph (TEG) Findings. TEG parameters
are presented in Table 1.
𝑅 time: sample incubated with 22.50mM CAPE
exhibited a significantly different𝑅 time than the nor-
mal controls but not with 15.00mM CAPE.
𝐾 time: there were no significant differences between
the normal controls, 15.00mM CAPE samples, or
22.50mM CAPE samples.
Alpha angle (𝛼): there were no significant differences
between the normal controls, 15.00mM CAPE sam-
ples, or 22.50mM CAPE samples.
Maximum amplitude (MA): there was a significant
decrease in MA for samples incubated with either
15.00 or 22.50mM CAPE compared with that of the
normal controls.
Table 1: Median interquartile range (IQR) for TEG findings in the
normal controls and CAPE.
Variable Normal controlmedian (IQR)
CAPE 15.00mM
median (IQR)
CAPE
22.50mM
median (IQR)
𝑅-time
(min) 5.90 (1.45) 3.50 (2.70) 3.05 (1.90)
𝐾-time
(min) 1.90 (0.40) 2.30 (2.10) 1.55 (1.03)
𝛼 angle
(degree) 64.80 (6.00) 61.50 (17.20) 69.60 (12.85)
MA (mm) 60.60 (3.65) 41.60 (19.80) 49.70 (10.15)
LY30 (%) 0.40 (1.15) 1.70 (5.05) 21.35 (11.85)
𝑅: reaction time;𝐾: clotting time; 𝛼: angle; MA: maximum amplitude; LY30:
clot lysis.
The LY30: the LY30 trended upward from the normal
control to the 15.00mM CAPE samples, but statisti-
cally insignificant. There were significant differences
between the normal controls and the 22.50mM sam-
ples as well as the 15.00 and 22.50mM samples.
All TEG parameters in the normal and 0.5% DMSO controls
showed insignificant differences.
4. Discussion
The present study used previously reported in vitro WB clot
lysis methods of fibrinolytic activity assessment to investigate
the concentration-dependent fibrinolytic activity of CAPE in
vitro [27]. TEGparameters, including a fibrinolytic parameter
(LY 30), were also measured to assess the effects of CAPE.
This study was an extension of a previous in vitro study that
reported that CAPE has time-dependent fibrinolytic activity
[30]. Plasma and solvent controls (DMSO) were used to
control the effect of fibrinolytic activity that occurs sponta-
neously with time and to exclude solvent-induced fibrinolysis
[30, 37]. The DD level tended to increase with increasing
CAPE concentration. In the early stages of this study, it
was found that three hours of CAPE led to significant and
consistent changes in fibrinolytic activities (e.g., DD levels)
than did one or two hours of CAPE incubation. However,
incubation with less than 3.75mM CAPE had no significant
effect on fibrinolysis, although effects below the sensitivity
threshold for the methods used to assess fibrinolysis in
vitro cannot be discounted. Blood tested in vitro with a
DD concentration greater than 0.50 𝜇g/mL strongly indicates
fibrinolytic activation in the blood clot because the threshold
DD level for normal pooled plasma is 0.50 𝜇g/mL (based on
the local lab reference value).
The study demonstrated that after incubation, different
concentrations of CAPE led to fibrinolytic activity in the
human blood clot model. A statistically significant difference
in the mean DD levels was observed between samples incu-
bated with different CAPE concentrations with the exception
of 15mM compared with 30mM and 22.50mM compared
with 30.00mM.These exceptions may be attributed to either
a limiting factor imposed by the fibrinolytic process or the
6 BioMed Research International
(a) Retracted (b) 3.75mM (c) 7.5mM
(d) 15mM (e) 22.5mM (f) 30mM
Figure 2: Confocal images for retractedWB clots treated with CAPE. (a) Image of normal retractedWBwithout CAPE treatment.The figure
demonstrates fibrin binding the RBCs in the retracted WB clot (control); the white arrow is pointing to the RBCs. (b) 3.75mM CAPE; the
fibrin is reduced on the RBCs. (c) 7.50mMCAPE; the fibrin level is less than in 3.75mMCAPE sample. (d, e, and f) 15.00, 22.50, and 30.00mM
CAPE, respectively; the fibrin is completely absent, leaving behind only RBCs that appear red in color (63x, magnification bar = 20 𝜇m).
fact that these concentrations gave a rather similar dose
effect. Incubation with 22.50mM CAPE led to higher DD
levels (peak), which declined progressively with increased
CAPE concentration. This decline was most likely due to the
peaking in the enzyme activity (plasminogen) which grad-
ually subsided. Mechanistically, fibrinolysis usually involves
the binding of plasminogen to fibrin and conversion to
plasmin (an active form of the plasminogen) by tissue-type
plasminogen activator (tPA). Plasmin then cleaves the fibrin
at specific sites producing fibrin degradation fragments that
can be used as markers of fibrinolysis by measuring DD [38].
In the present study, the observed increase in DD is most
likely due to plasminogen activation by CAPE. However, the
exact mechanism of activation needs to be determined in
future studies especially in vivo.The sigmoid curve in Figure 1
reaches a plateau after 22.5mM which actually explains the
rate-limiting factor in the fibrinolytic procedure.
Our study is the first to report on the ED
50
of CAPE,
which was determined to be 1.99mg/mL. Previous reports
of the ED
50
of various compounds, drugs, or thrombolytic
agents that have been studied for effects on plasma clot lysis
have utilized clot turbidity as a marker to determine clot
mass following incubation with 6% bovine serum albumin-
(BSA-) phosphate-buffered saline (PBS) and pooled normal
human plasma. The ED
50
of fresh clot lysis for BSA and
pooled normal human plasma were found to be relatively
low at 128 and 180 IU/mL (urokinase), 0.3 and 0.2 𝜇g/mL
(t-PA), 215 and 1371 IU/mL (streptokinase), 60 and 91U/mL
(plasminogen-streptokinase activator complex), 664 and
996U/mL (reteplase), and 0.2 and 0.2 𝜇g/mL (tenecteplase),
respectively [39]. However, the methods used to assess clot
lysis were different; the Microtiter Plate Clot Lysis Assay was
used [39].
The relationship between DD level and CAPE concen-
tration was nonlinear above 22.50mM CAPE, most likely
because of the rate-limiting effects of the fibrinolytic enzyme.
This finding correlated with a previous study that reported a
nonlinear increase in DD concentration using plasma clots
in recombinant tissue plasminogen activator- (rt-PA-) based
fibrinolysis [40]. In this study, retracted WB clots were used
as they are more suitable than plasma clots for evaluating
coagulation parameters, as previously reported [27, 30, 41].
The WB clots also mimic in vivo clot formation better than
plasma clots, as RBCs and white blood cells (WBCs) are part
of the clot structure.
The antioxidant, immunomodulatory, anti-inflamma-
tory, antiplatelet, and time-dependent fibrinolytic activities
of CAPE have previously been reported [30, 37, 42–44]. Our
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study is the first to investigate the fibrinolytic activity of
CAPE at different concentrations using in vitro methods.
This study is similar to a previous study that used tPA-
induced fibrinolysis at a higher temperature to cleave the
fibrinogen and fibrin in a thrombus into fragments D and E,
as quantified by measurement of the DD concentration. DD
is a specific marker for fibrin degradation [40]. This study
agreed with the earlier reports that also used DD, hemo-
globin, and radioactive 125I-fibrinogen to evaluate clot lysis
activity.These different parameters tended to increase [30, 45,
46], indicating evidence of fibrinolytic activity.
In the present study, theWBclotweightwas used to inves-
tigate clot lysis activity. The median WB clot weight post-
CAPE incubation was significantly lower than the median
pre-CAPE incubation clot weight for every CAPE concen-
tration tested. These results agree with previously published
studies [3, 27, 30, 40, 47, 48]. However, no significant differ-
ences inweightwere observed among samples incubatedwith
different CAPE concentrations, although significant weight
reduction was observed in some of the groups.The sensitivity
of using WB clot weight to detect fibrinolytic activity has
been shown to be lower than the sensitivity achieved using
DD levels [27]. Samples incubatedwith 22.50mMCAPEwere
significantly different than samples incubated with 3.75, 7.50,
or 15.00mMCAPE,whichmay indicate that 22.50mMCAPE
has a more obvious effect on clot lysis in vitro that is similar
to the effect of 30.00mM CAPE.
The current in vitro study assumed a concentration-
dependent CAPE effect, in accordance with the former study
that demonstrated a dose-dependent CAPE effect (at 1, 5, 10,
and 20mg/kg) when injected intravenously in rats (in vivo)
as determined by evaluating heart rate and blood pressure.
The lethal dose of CAPE was found to be 20mg/kg for rats
[7]. Previous studies have reported that fibrinolytic enzymes
can be found in a variety of foods, such as Japanese Natto,
Tofuyo, Korean Chungkook-Jang soy sauce, and soybean
flour (Bacillus subtilisK42). Another strain of Bacillus subtilis
LD-8 47 was isolated from douchi, a traditional Chinese
soybean-fermented food, and XZNUM 00004 was extracted
from Streptomyces sp. and edible honey mushrooms [4, 5,
23, 24, 26]. Furthermore, a recombinant CGK study in
mice demonstrated protection from death due to pulmonary
embolism using various doses of this substance including 130,
260, and 520mg/kg [25].
Microscopy is best suited to determine fine details and
information of fibrin clot structures [27, 28]. In the present
study, WB clots incubated in different concentrations of
CAPE showed fibrin removal from RBCs after 3 hrs of incu-
bation that disappeared at the higher concentrations. A pre-
vious study revealed increased porosity of fibrin when treated
with thrombin and factor Xa inhibitors using 3D confocal
microscopy [49]. This study agreed with a former study that
performed qualitative assessment of WB clot morphology
using confocal microscopy [27].The effect of CAPE on fibrin
imaging was evaluated by comparing treated samples with
untreated fibrin as shown by the representative image in
Figure 2. The WB clot confocal images demonstrated that
the fibrin fibers were prominent and surrounded by RBCs
in the control sample but not in the CAPE-treated clots. The
fibrin network was suddenly lost in WB clots and no fibrin
fibers were visible when clots were incubated with different
CAPE concentrations. At concentrations of 3.75 and 7.50mM,
a reduced fibrin meshwork was observed as an orange color
(indicating a combination of green fibrin and red RBCs).
Ultimately, the fibrin fibers vanished or disappeared with
higher concentrations of CAPE (15.00, 22.50, and 30.00mM).
A fibrin clot is a three-dimensional network made up
of fibers with unique mechanical properties that explain the
correlation between clot structure and the mechanical and
fibrinolytic stability of clots [38]. In this study, the fibrin
fibers were removed faster in CAPE-incubated clots than in
plasma-treated (control) clots, as shown in a previous study
[27] using streptokinase. This observation reflects the effect
of penetration of CAPE into theWB clot.The structure of the
fibrin networks underwent significant changes in architecture
during the lytic process [28, 29, 49].
In this study, only two concentrations of CAPE (15.00
and 22.50mM) were used for the TEG assay. These CAPE
concentrations were selected because they led to significant
changes inDD levels (Figure 1).TheTEGparameters for clots
incubated with 15.00 and 22.50mM CAPE were different,
indicating different hemostatic activities. There was no sol-
vent effect from the DMSO in which the CAPEwas prepared.
The TEG parameter 𝑅 time was lower in both CAPE-
incubated samples than in the normal controls. Based on
the pattern of the TEG tracing, CAPE may activate coagu-
lation factors in vitro shortening the 𝑅 time. Another TEG
parameter, 𝐾 time, showed insignificant differences between
the normal controls and different CAPE concentrations. A
possible reason for this observation is that CAPE does not
possess anticoagulant properties and, therefore, does not
lead to differences. Another TEG parameter, alpha angle (𝛼),
tended to increase at 22.50mMCAPE. Previous reports have
described TEG changes under selected conditions [34, 36].
CAPE has been reported to have antiplatelet properties. In
this study, however, no antiplatelet effect of CAPE was shown
based on the alpha angle parameter, although there was an
increase in alpha angle values when a higher dose of CAPE
(22.5mM) was used.
The next TEG parameter, MA, was significantly reduced
in samples incubated with both concentrations of CAPE
comparedwith normal controls.MAvalues, however, showed
continuous reduction over time, which may indicate the
fibrinolytic effects of CAPE [34] because MA is a function
of both fibrin and platelet dynamic properties. Therefore,
the antiplatelet and fibrinolytic effect of CAPE may have
contributed to the reducedMA value. Lastly, the TEG param-
eter LY30 showed the fibrinolytic activity of CAPE using
TEG method. Additionally, fibrinolysis can be indicated by
a normal 𝑅 time and a disproportionately decreasing MA
value over time. Fibrinolytic activity measure by the TEG
parameter LY30 might not correlate perfectly with DD levels
as fibrin degradation produces different split products other
than DD [36].
In this study, different techniques have been used to assess
the fibrinolytic activity of CAPE at different concentrations.
Although all the results showed evidence of fibrinolytic effect
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of CAPE, there are still some slight differences. For example,
DD detects fibrinolytic activity at the molecular level in the
presence of split products of fibrin degradation, while clot
weight is a crude procedure which may not be sensitive
enough to indicate CAPE’s fibrinolytic effects. TEG param-
eter is a good tool which can show fibrinolysis activity based
on the dynamic changes of the blood clot.Themorphological
assessment detects fibrin dissolution very early even at the
lowest dose of CAPE.The confocal microscopy which detects
structural changes of fibrin may be influenced by many
factors including CAPE concentration, buffers, dyes, andWB
clot size used for confocal microscopy.
In this study, the dose response curve (Figure 1) showed
a range of CAPE concentrations. Although practically this
may not be possible (very high concentration was included,
i.e., 30.00mM of CAPE), natural product containing CAPE
may illustrate synergistic effects with other compounds, in
particular with other phenolic substances. Therefore, vari-
abilities in fibrinolytic effects may be yielded, which is hoped
to be overcome when high CAPE concentrations are used.
Although not reported here, the fibrinolytic effects of crude
propolis using DD has been shown to be higher than that of
CAPE alone.Therefore, further investigations are required in
the future to confirm this finding.
There are many expected limitations in in vitro studies.
In this study, the effects of pH and ionic strength in the tests
system were not critically evaluated. However, normal and
solvent controls were included to mitigate this effect. The
normal control and solvent control were included.The effects
of the pure compound which is free from influences of other
factors should be investigated and reconfirmed.
5. Conclusion
This study demonstrates that at 3 hours of incubation CAPE
has dose-dependent fibrinolytic activity in vitro. CAPE has
a fibrinolytic potential to gradually lyse WB clots in vitro,
suggesting that it could be used as an alternative thrombolytic
agent in the future. More studies are required to evaluate
the biological effects of CAPE and to confirm its fibrinolytic
potential for in vivo use.
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